EGFR and head and neck squamous cell carcinoma: Basavaraj et al (12) reported the results of a phase II clinical trial in which 92 patients with advanced head and neck squamous cell carcinoma received standard therapy with or without nimotuzumab, a humanized monoclonal antibody that recognizes domain III of the extracellular region of the epidermal growth factor receptor.